COMMUNIQUÉS West-GlobeNewswire

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
20/04/2026
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical- [...]
Tilray Brands Marks 4/20, Reaffirming Its Leadership in Cannabis and Commitment to Advancing Medical Care
20/04/2026
NEW YORK and LEAMINGTON, Ontario, April 20, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of [...]
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
20/04/2026
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
20/04/2026
Company Advances Next-generation Patented MDMA Toward Patient Dosing in 2026 TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) ("PharmAla" or the "Company"), a global [...]
Omega Laboratories to Host Educational Panels and Present Cannabix Marijuana Breath Test Solution at the 2026 NDASA Conference in California
20/04/2026
VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana and alcohol breath-testing [...]
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
20/04/2026
First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runway Trading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: [...]
Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
20/04/2026
ORION CORPORATION PRESS RELEASE 20 APRIL 2026 at 16.00 EEST Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA Orion Corporation (Orion Pharma) today announced that its investigational [...]
Baba Appoints Former Mount Sinai Executive Director to Lead Clinical Operations
20/04/2026
Platform taps decade+ of health system clinical leadership to scale virtual, longitudinal advocacy for Medicare, Medicare Advantage, and Medicaid populations NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Baba, an [...]
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
20/04/2026
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
20/04/2026
Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in [...]
Vystar Enters into Binding Letter of Intent to Acquire 50% Interest in R3alm Inc.
20/04/2026
A Compliance-Focused AI and Web3 Financial Ecosystem Proposed Transaction Includes Joint Development Framework, Vystar Series B Consideration, and Strategic Alignment Around the R3EQ Ecosystem ■ ■ ■ Vystar to Receive [...]
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
20/04/2026
AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector [...]
Nanox Signs Commercial Agreement with Howard Technology Solutions to Deploy 300 Nanox.ARC Systems Across U.S. Over Three Years
20/04/2026
Howard’s nationwide reach across healthcare and public sector markets expands Nanox’s U.S. channel partner network to additional customer segments PETAH TIKVA, Israel, April 20, 2026 -- Nano-X Imaging Ltd. (“Nanox”, or [...]
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
20/04/2026
Boehringer is expanding its global Computational Innovation footprint with a new center dedicated to AI and machine learning (ML) in the UK Establishing a presence in King’s Cross, London, places Boehringer at the heart [...]
Axe Compute Unveils Compute Reserve Dashboard, Giving Investors a Unified View of Its NASDAQ Stock and Operational Strategic Compute Reserve
20/04/2026
Purpose-built for the neocloud era: a unified view of Axe Compute's NASDAQ equity and its Strategic Compute Reserve (SCR), the operational reserve that funds enterprise access to 435,000+ GPUs across 200+ global [...]
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
20/04/2026
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” time, reductions in “Off [...]
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
20/04/2026
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical [...]
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
20/04/2026
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection Received US patent allowance covering proprietary gas delivery technology for [...]
Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
20/04/2026
Patient screening to begin this month DURHAM, N.C., April 20, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse [...]

Pages